SUPRIYA919.40

Supriya Lifescience Ltd.

· Pharma & Health
AnnualQuarterly₹ CrorePeersSTARSPARCTHYROCARESHILPAMEDVIYASHRUBICONYATHARTHPARKHOSPS
View
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
Last 12M
30/06/2026
Revenue from Operations872.5
Other Income11.5
Total Income884.0
Expenses
+ Cost of Materials Consumed330.7
+ Changes in Inventories-52.1
+ Employee Benefit Expense102.5
+ Finance Costs1.8
+ Depreciation & Amortisation30.9
+ Other Expenses201.6
Total Expenses615.4
EBITDA289.8
EBIT258.9
Profit
PBT before Exceptional Items268.6
+ Exceptional Items-0.5
Pretax Income268.2
+ Current Tax59.4
+ Deferred Tax10.4
Tax Expense69.8
Net Income198.4
+ Net Income — Continuing Ops198.4
+ Other Comprehensive Income0.8
Total Comprehensive Income199.1
Per Share
Basic EPS24.65
Diluted EPS24.65
Other Comprehensive Income — detail
+ Other Comprehensive Income0.8
+ Items NOT to be Reclassified to P&L1.0
+ Tax on Items NOT to be Reclassified0.3
Per Share — as-filed variants
Basic EPS — Continuing Operations24.65
Diluted EPS — Continuing Operations24.65
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit593.9
Gross Margin %68.07
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)268.6
− Exceptional Items (reconciliation)-0.5
Net Income Adj (tax-effected)198.7
EPS Adj24.69
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value2.00
Paid Up Equity Capital16.1
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY25 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 89%.